Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This meta-analysis found that patients with alopecia areata have significantly higher odds of also having immune-mediated diseases such as atopic dermatitis, autoimmune thyroiditis, inflammatory bowel disease, systemic lupus erythematosus, and vitiligo, suggesting a need for comprehensive screening and interdisciplinary management.

This narrative review found that post-COVID-19 hair loss, particularly telogen effluvium, poses a significant mental and social burden, with minoxidil potentially aiding recovery, although more clinical research is needed to confirm its effectiveness.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

This letter to the editor notes a case where alopecia developed as pemphigus foliaceus transitioned to pemphigus vulgaris; it provides no new experimental findings.

Hair changes may indicate disease activity in pemphigus patients.

This article reports no new clinical findings and provides no abstract, focusing on imipramine-induced lesions resembling alopecia areata.

This study found that the genetic variants rs231775 and rs3087243 of the CTLA4 gene are not associated with alopecia areata in the Mexican population analyzed.

This report documents the first known association of alopecia areata with idiopathic primary hypophysitis, suggesting a shared autoimmune basis.

Harris et al. describe a new mouse model for vitiligo, where interfollicular melanocytes are retained and melanocyte-targeting immune responses are simulated, aiding the development of immunomodulatory therapies.

In this case report, a severe case of pediatric alopecia areata was treated with topical ruxolitinib, a Janus kinase inhibitor, highlighting the limited but promising evidence for this treatment in children.

Fumaric acid esters might help treat alopecia areata, but more research is needed.

This case report describes a patient in whom vitiligo was induced by diphenylcyclopropenone treatment for alopecia universalis, highlighting the potential overlap of susceptibility genes between the two conditions.

This review discusses various treatment options for alopecia areata, noting a lack of consensus on grading and treatment algorithms, and reports no new clinical results.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This review discusses the characteristic trichoscopy patterns useful in differentiating lichen planopilaris and frontal fibrosing alopecia from similar conditions but reports no new clinical results.

This study found that scalp hair loss is the most bothersome symptom of alopecia areata for both adults and adolescents, highlighting the need for treatments focused on improving scalp hair growth.

This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement.

This letter to the editors discusses the nature of alopecia in Cronkhite–Canada syndrome and questions whether it is truly telogen effluvium, but it reports no new clinical findings.

This study observed that transverse sectioning of scalp biopsies may aid in diagnosing different types of alopecia by revealing distinct histopathological features like follicle miniaturization and specific inflammatory patterns.

This letter to the editor discusses the occurrence of alopecia areata, thyroiditis, and vitiligo in a Japanese patient with smoldering type adult T-cell leukemia/lymphoma, but it reports no new research findings.

Telogen Effluvium is a hair loss condition where treatment involves identifying and managing its triggers.

This review discusses recent advances in hair follicle research, highlighting therapeutic and cosmetic applications, but reports no new study results.

This article reviews the diagnosis and treatment of clinical hair loss without providing new clinical results.

This study found that patients with lichen sclerosus et atrophicus who have autoimmune-related phenomena do not experience a different natural history of the disease compared to those without such phenomena.

This narrative review reports that Janus kinase inhibitors show promise as an effective treatment for alopecia areata, especially in patients who do not respond to conventional therapies, although further research on long-term use and topical application is needed.

This case report highlights the onset of alopecia areata following dupilumab treatment, noting the significant temporal link between the medication use and hair loss occurrence.

This article discusses advancements and methodologies in epitope identification for autoimmune diseases, specifically alopecia areata, but does not report new experimental results.

Hair loss in Cronkhite-Canada syndrome may be due to an autoimmune response.

AUC and APL are distinct conditions needing careful clinical assessment.

IL-27 may help prevent hair loss by creating immune-suppressing cells.